Bromocriptine is a dopamine D2 receptor agonist that acts on the hypothalamus and reduces dopaminergic activity, potentially modulating neurotransmitter pathways involved in cluster headache pathogenesis. By binding to D2 receptors, it can decrease prolactin secretion and influence neurovascular regulation, which may help mitigate the frequency and intensity of cluster headache episodes.